Radiation sensitizing effect of estramustine is not dependent on apoptosis

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 2873-2878

  Ståhlberg, Kaarlo ^a   Kairemo, Kalevi ^a   Erkkilä, Krista ^a   Pentikäinen, Virve ^a   Sorvari, Pekka ^a   Taari, Kimmo ^a   Dunkel, Leo ^a   Rannikko, Sakari ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

DU 145; Estramustine; Prostate cancer; Radiotherapy; Testis; Xenograft

Indexed keywords

DNA FRAGMENT; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; FOLLOW UP; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION EXPOSURE; RADIOSENSITIZATION; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA FRAGMENTATION; ESTRAMUSTINE; HUMANS; MALE; MICE; MICE, NUDE; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 22944480554     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Zelek L, Barthier S, Riofrio M, Sevin D, Fiazazi K and Spielmann M: Single-agent estramustine phosphate (EMP) is active in advanced breast cancer after failure with anthracyclines and taxanes. Ann Oncol 12(9): 1265-1268, 2001.
2. Vallbo C, Bergenheim AT, Bergström P, Gunnarsson PO and Henriksson R: Apoptotic cell death induced by estramustine in patients with malignant glioma. Clin Cancer Res 4: 87-91, 1998.
3. Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G and Leone L: A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer 94(6): 1654-1660, 2002.
4. Ben-Josef E, Porter AT, Han S, Mertens W, Chuba P, Fontana J and Hussain M: Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results. Int J Radiat Oncol Biol Phys 49(3): 699-703, 2001.
5. Zelefsky MJ, Kelly WK, Scher HI, Lee H, Smart T, Metz E, Schwartz L, Fuks Z and Leibel SA: Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol 18(9): 1936-1941, 2000.
6. Eklov S, Westlin JE, Rikner G and Nilsson S: Estramustine potentiates the radiation effect in human prostate tumor transplant in nude mice. Prostate 24(1): 39-45, 1994.
7. Eklov S, Essand M, Carlsson J and Nilsson S: Radiation sensitization by estramustine studies on cultured human prostatic cancer cells. Prostate 21(4): 287-295, 1992.
8. Ryu S, Gabel M, Khil MS, Lee YJ, Kim SH and Kim JH: Estramustine: a novel radiation enhancer in human carcinoma cells. Int J Radiat Oncol Biol Phys 30(1): 99-104, 1994.
9. Edgren M and Lennernas B: Estramustine a radio sensitising agent. Anticancer Res 20(4): 2677-2680, 2000.
10. Kim JH, Khil MS, Kim SH, Ryu S and Gabel M: Clinical and biological studies of estramustine phosphate as a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 29(3): 555-557, 1994.
11. Bergenheim AT, Zackrisson B, Elfverson J, Roos G and Henriksson R: Radiosensitising effect of estramustine in malignant glioma in vitro and in vivo. J Neurooncol 23(3): 191-200, 1995.
12. Panda D, Miller HP, Islam K and Wilson L: Stabilization of microtubule dynamics by estramustine binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci USA 94(20): 10560-10564, 1997.
13. Dahllöf B, Billström A, Cabral F and Hartley-Asp B: Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res 53: 4573-4581, 1993.
14. Vallbo C, Bergenheim T, Bergh A, Grankvist K and Henriksson R: DNA fragmentation induced by the antimitotic drug estramustine in malignant rat glioma but not in normal brain - suggesting an apoptotic cell death. Br J Cancer 71: 717-720, 1995.
15. Darby E, An S, Ng C, Hsieh TC, Mallouh C and Wu JM: Effects of microtubule inhibitors - taxol, vinblastine and estramustine on the growth and p53 gene expression in the hormone independent human prostatic JCA-1 cells. Anticancer Res 16: 3647-3652, 1996.
16. Yoshida D, Piepmeier JM, Bergenheim T, Henriksson R and Teramoto A: Suppression of matrix metalloproteinase-2-mediated cell invasion in U87MG, human glioma cells by antimicrotubule agent: in vitro study.
17. Sklar GN, Eddy HA, Jacobs SC and Kyprianou N: Combined antitumor effect of suramin plus irradiation in prostate cancer cells: the role of apoptosis. J Urol 150: 1526-1532, 1993.
18. Johansson M, Bergenheim AT, Henriksson R, Koskinen LO, Vallbo C and Widmark A: Tumor blood flow and the cytotoxic effects of estramustine and its constituents in a rat glioma model. Neurosurgery 41: 237-244, 1997.